Effect of benchmarking projects on outcomes of coronary artery bypass graft surgery: Challenges and prospects regarding the quality improvement initiative  by Miyata, Hiroaki et al.
Acquired Cardiovascular Disease Miyata et al
A
C
DEffect of benchmarking projects on outcomes of coronary artery
bypass graft surgery: Challenges and prospects regarding the quality
improvement initiativeHiroaki Miyata, PhD, Noboru Motomura, PhD, MD, Arata Murakami, PhD, MD, and
Shinichi Takamoto, PhD, MD, for the Japan Cardiovascular Surgery DatabaseFrom th
Funding
sociat
Labou
Disclosu
Receive
public
Address
Asses
Bunk
0022-52
Copyrig
doi:10.1
1364Objective: The Japan Cardiovascular Surgery Database (JCVSD) was established in 2000 and initiated a bench-
marking project to improve the quality of cardiovascular surgery. Although the importance of quality improve-
ment initiatives has been emphasized, few studies have reported the effects on outcomes.
Methods: To examine the time-trend effects in initial JCVSD participants (n ¼ 44), we identified 8224 isolated
coronary artery bypass graft (CABG) procedures performed between 2004 and 2007. The impact of surgery year
was examined using a multiple logistic regression model that set previously identified clinical risk factors and
surgery year as fixed effects. To examine the difference in outcomes between initial participants (n ¼ 44) and
halfway participants (n¼ 55), we identified 3882 isolated CABG procedures performed in 2007. The differences
between the 2 hospital groups were examined using a multiple logistic regression model that set clinical risk
factors, hospital procedure volume, and hospital groups as fixed effects.
Results: For operative mortality, the odds ratio of surgery year was 0.88 (P ¼ .083). Observed/expected (OE)
ratios for operative mortality were 0.71 in 2004, 0.73 in 2005, 0.63 in 2006, and 0.54 in 2007. As for composite
mortality and major morbidities (reoperation, stroke, dialysis, infection, and prolonged ventilation), odds ratio
of surgery year was 0.97 (P ¼ .361). OE ratios for composite mortality and morbidities were 1.01 in 2004, 1.04
in 2005, 1.04 in 2006, and 0.94 in 2007. Compared with halfway participants, initial participants had a signifi-
cantly lower rate of operative mortality (odds ratio¼ 0.527; P¼ .008) and composite mortality and major mor-
bidities (odds ratio 0.820; P ¼ .047).
Conclusions: This study demonstrated that a quality improvement initiative for cardiovascular surgery has pos-
itive impacts on risk-adjusted outcomes. Although the primary target of benchmarking was 30-day mortality in
Japan, major morbidities were less affected by those activities. (J Thorac Cardiovasc Surg 2012;143:1364-9)As the Institute of Medicine1 has indicated by making the
concept of ‘‘patient-centered’’ a centerpiece of 21st century
health care reform, it is critical to make benefits to patients
the central focus of health care in the future. In contrast to
the ‘‘patient-centered’’ mission statements of professional
committees, containing medical costs is often the central
concern in health care policy issues. However, the chief ob-
jective of health care is the provision of the best service to
patients, not the reduction of medical costs.2 Thus, it is im-
portant to examine how to design and adjust systems to
achieve that objective, including treatment fees for medicale Japan Cardiovascular Surgery Database.
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care, and other practical efforts.
In considering improvements to the quality of health
care, it is necessary to define, understand, and evaluate
‘‘performance.’’ When constructing an index that demon-
strates this ‘‘performance’’ in health care, it is important
to make use of treatment results adjusted for the risks of in-
dividual patients.3-5 A framework must also be constructed
that provides feedback in the form of accurate information
that can be understood and accepted at the level of clinical
practice and that can be used to improve the quality of
health care.4 For such a framework to be constructed, a na-
tionwide clinical database that provides an infrastructure
for conducting systematic data collection and empirical
analysis in collaboration with clinical practice is needed
for each specialty.
The Japan Cardiovascular Surgery Database (JCVSD)
was established in 2000 and initiated a benchmarking pro-
ject to improve the quality of cardiovascular surgery.6-9
As of 2010, JCVSD has captured clinical information
from more than 300 hospitals across Japan and is
considered a nationwide quality improvement initiative.
Although the importance of quality improvementgery c June 2012
Abbreviations and Acronyms
CABG ¼ coronary artery bypass graft
JCVSD ¼ Japan Cardiovascular Surgery
Database
OE ¼ observed/expected
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Miyata et al Acquired Cardiovascular Disease
A
C
Dinitiatives has been emphasized, few studies have reported
the effects on outcomes. In this study, we examine the
effect of benchmarking projects on the outcomes of
coronary artery bypass graft (CABG) surgery to clarify
challenges and prospects regarding the quality
improvement initiative.
METHODS
The JCVSD data collection form regarding CABG surgery has a total of
255 variables, which are almost identical to those used in The Society of
Thoracic Surgeons National Database (available at: http://www.sts.org).
Definitions of JCVSD variables (available at: http://www.jacvsd.umin.jp)
are also based on those of The Society of Thoracic Surgeons National
Database. The primary outcome measure of JCVSD analysis was 30-day
operative mortality, defined as either 30-day mortality or death before hos-
pital discharge. Major morbidity was defined as any of the following post-
operative in-hospital complications: stroke, reoperation for any reason,
postoperative mechanical ventilation required for greater than 24 hours,
renal failure, or deep sternal wound infection.10 Through the JCVSD
Web-based system, each participating hospital not only enters data but
also uses a feedback report in real time that includes risk-adjusted out-
comes compared with all participating hospitals. Although participation
in the JCVSD is voluntary, submissions tend to be thorough, with overall
preoperative risk factors used in risk models missing in fewer than 3%
of entries. The accuracy of submitted data is verified throughmonthly visits
to each hospital by The Site Visit Working Group. The Site Visit Working
Group member verifies that the number of procedures from the original op-
erative record list in the hospital matches the number of JACVSD data. The
Site Visit Working Group members also examine each clinical chart of pro-
cedures and compare it with the inputted JACVSD data. In addition to the
source document verification, all hospital data are also confirmed by inde-
pendent comparisons of hospital adult cardiovascular surgery volume sub-
mitted to the JCVSD against that reported to the Japanese Association for
Thoracic Surgery annual survey. We identified all cardiovascular proce-
dures performed between January 1, 2005, and December 31, 2008.
Statistical Analysis
We divided participating hospitals into 2 groups: initial JCVSD partic-
ipants that began submitting data before 2005 and halfway participants that
began submitting data to JCVSD in 2005 or later. To examine the time–
trend effects of initial JCVSD participants (n¼ 44), we identified 8224 iso-
lated CABG procedures performed between 2004 and 2007. We examined
differences among procedure years using bivariate tests: c2 test for categor-
ical covariates and 1-way analysis of variance for continuous covariates.
The impact of surgery year was examined using a multiple logistic regres-
sion model that set previously identified clinical risk factors11 and surgery
year as fixed effects. Risk-adjusted mortality rates for each category were
calculated by dividing the observed outcome rate by the expected outcome
rate at the same hospital and multiplying by the overall raw outcome rate of
the JCVSD. We examined differences among procedure year using bivari-
ate tests: c2 test for categorical covariates and t test for continuousThe Journal of Thoracic and Carcovariates. To examine differences in outcomes between initial participants
(n ¼ 44) and halfway participants (n ¼ 55), we identified 1825 isolated
CABG procedures performed in 2007. We conducted 2 comparisons: (1)
procedure performed at initial participants in 2004 versus procedure per-
formed at halfway participants in 2007; (2) procedure performed at initial
participants in 2007 versus procedure performed at halfway participants in
2007. The differences between the 2 groupswere examined using amultiple
logistic regression model that set clinical risk factors,11 hospital procedure
volume, and hospital groups as fixed effects.RESULTS
Patient characteristics of isolated CABG operations in
the initial participating hospitals are displayed in Table 1.
The total number of procedures was 8224 (1831 procedures
in 2004, 2211 in 2005, 2125 in 2006, and 2057 in 2007).
Prevalence rates of diabetes, chronic obstructive pulmonary
disease, extracardiac disease, severe heart failure (New
York Heart Association class IV), and left main coronary ar-
tery disease were significantly different between procedure
years. Preoperative risks and observed/expected (OE) out-
come ratios for isolated CABG surgery in initial partici-
pants are displayed in Table 2. Although the OE mortality
ratio decreased each year (odds ratio [OR] ¼ 0.87;
P ¼ .083), the OE morbidity ratio remained virtually un-
changed (OR ¼ 0.972; P ¼ .0361).
In Table 3, patient characteristics of isolated CABG oper-
ations in 2007 are shown for halfway JCVSD participants
(n ¼ 55) in addition to initial participants (n ¼ 44). Preva-
lence rates of renal failure, chronic obstructive pulmonary
disease, extracardiac disease, cardiogenic shock, and reop-
eration were significantly different between initial and half-
way participants. Preoperative risks and OE outcome ratios
in ‘‘2004 initial participant’’ and ‘‘2007 halfway partici-
pant’’ are displayed in Table 4. Neither the OE mortality ra-
tio nor the OE morbidity ratio was significantly different.
Preoperative risks and OE outcome ratios in ‘‘2007 initial
participants’’ and ‘‘2007 halfway participants’’ are dis-
played in Table 5. Both the OE mortality ratio and the OE
morbidity ratio were significantly different between initial
and halfway participants.DISCUSSION
In the Japanese cardiac surgery field, there was a signifi-
cant improvement inmortality rates at facilities participating
in the quality improvement initiative. In addition, compared
with hospitals that began participating halfway through the
project, bothmorbidity andmortality rateswere significantly
lower for hospitals participating from the beginning, even
when the number of annual cases and preoperative risk
were considered. As many previous studies indicate,12,13
these results suggest that participation in benchmarking
projects impacts the improvement of performance
indicators targeted for measurement. This is because
clinical departments in participating hospitals increase
awareness of improvement indicators by reportingdiovascular Surgery c Volume 143, Number 6 1365
TABLE 1. Patient characteristics of initial JCVSD participants (n ¼ 44)
2004 2005 2006 2007 P value
No. of procedures 1831 2211 2125 2057
Age (mean  SD) (y) 67.5  9.5 67.8  9.4 68.1  9.6 68.1  9.5 .212
Male gender (%) 78.6 76.9 78.2 77.8 .598
Diabetes (%) 46.8 47.8 51.1 48.4 .039
Renal failure (%) 13.4 14.4 15.6 13.9 .228
Cerebrovascular disease (%) 11.7 13.9 13.3 13.8 .167
Chronic obstructive pulmonary disease (%) 4.9 6.0 5.5 7.7 .002
Extracardiac disease (%) 12.8 14.4 14.3 17.2 <.001
Cardiogenic shock (%) 4.3 5.8 4.9 4.9 .166
NYHA class IV (%) 10.4 10.2 7.3 8.8 .001
Triple vessel disease (%) 68.2 68.8 70.7 70.5 .227
Left main disease (%) 33.9 37.4 37.3 39.4 .005
LV function (poor) (%) 8.0 6.6 7.4 6.5 .220
Reoperation (%) 3.2 2.8 2.5 3.4 .384
Operation status
Urgent (%) 13.5 13.5 11.4 11.6 .059
Emergency, salvage (%) 7.0 8.3 6.5 5.8 .014
JCVSD, Japan Cardiovascular Surgery Database; SD, standard deviation; NYHA, New York Heart Association; LV, left ventricular.
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the hospitals become aware of their own characteristics and
challenges by analyzing their position relative to national
averages. Thus, participation in a benchmarking project
that uses a clinical database constitutes the first step
toward improving the quality of medical care. This in itself
fulfills a certain social responsibility that the profession
carries.5,13 However, although an understanding of medical
standards based on unified criteria and third-party data veri-
fication are necessary conditions for improving the quality of
medical care, they are insufficient. A clear strategy in coor-
dination with the clinical setting should be implemented to
further improve the quality of medical care. To this end, it
would be informative to examine combinations of the strat-
egy with individual methods, such as the implementation of
improvement policies in coordination with insurers4 or the
sharing of best practices in coordination with the clinical
setting.14TABLE 2. Time-trend outcomes of initial JCVSD participants (n ¼ 44)
2004 200
Mortality
Raw operative mortality rate (%) 2.30 2.5
Preoperative operative mortality risk (%) 3.25 3.4
OE mortality ratio 0.71 0.7
Morbidity
Raw major morbidity rate (%) 13.40 14.2
Reoperation for any reason (%) 5.2 5.9
Stroke (%) 1.5 1.4
Dialysis newly required (%) 2.8 3.1
Deep sternal wound infection (%) 1.1 2.0
Prolonged ventilation (>24 h) (%) 6.5 6.1
Preoperative major morbidity risk (%) 13.29 13.6
Observed/expected morbidity ratio 1.01 1.0
JCVSD, Japan Cardiovascular Surgery Database; OR, odds ratio; OE, observed/expected.
1366 The Journal of Thoracic and Cardiovascular SurAlthough there was a trend of improvement in the mortal-
ity rate of CABG surgery, the trend in morbidity rate was
flat. There was a difference in the morbidity rate between
facilities that participated from the beginning and those
that began participating midway through the project, even
in 2007. Nevertheless, the difference in mortality rates
was slight. A potential factor underlying the slight improve-
ment in morbidity rate relative to mortality rate is that
benchmarking in the cardiac surgery field in Japan has
been directed at perioperative mortality as represented by
30-day mortality. Independently of JCVSD, the Japanese
Association for Thoracic Surgery conducts annual surveys
based on guidelines of The American Association for Tho-
racic Surgery.15 The response rates are extremely high and
cover all areas of Japan.16 The outcomes collected in this
survey include only 30-day mortality and in-hospital mor-
tality and do not include complications. In contrast, data
on more than 30 complications are collected in the JCVSD.5 2006 2007 Effect of surgery year
0 2.30 1.80 OR ¼ 0.878
(0.758-1.017)
P value ¼ .083
3 3.65 3.35
3 0.63 0.54
0 14.20 12.90 OR ¼ 0.972
(0.915-1.033)
P value ¼.361
7.2 5.8
1.6 1.4
2.7 1.9
1.7 1.6
5.6 5.6
2 13.66 13.71
4 1.04 0.94
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TABLE 3. Comparison of patient characteristics between initial and
halfway JCVSD participants in 2007
Initial
participants
(n ¼ 44)
Halfway
participants
(n ¼ 55)
P
value
No. of procedures 2057 1825
Age (mean  SD) (y) 68.1  9.5 68.3  9.3 .468
Male gender (%) 77.8 76.5 .338
Diabetes (%) 48.4 49.5 .479
Renal failure (%) 13.9 11.6 .034
Cerebrovascular disease (%) 13.8 14.8 .358
Chronic obstructive
pulmonary disease (%)
7.7 5.1 .001
Extracardiac disease (%) 17.2 14.2 .012
Cardiogenic shock (%) 4.9 3.2 .009
NYHA class IV (%) 8.8 10.4 .090
Triple vessel disease (%) 70.5 71.5 .501
Left main disease (%) 39.4 40.5 .491
LV function (poor) (%) 6.5 6.0 .551
Reoperation (%) 3.4 2.1 .024
Operation status (urgent) (%) 11.6 13.2 .156
Operation status (emergency,
salvage) (%)
5.8 7.3 .060
JCVSD, Japan Cardiovascular Surgery Database; SD, standard deviation;NYHA, New
York Heart Association; LV, left ventricular.
TABLE 5. Comparison of outcomes: ‘‘initial JCVSD participants
2007’’ versus ‘‘halfway JCVSD participants 2007’’
Initial
participants
2007 (n ¼ 44)
Halfway
participants
2007 (n ¼ 55)
Effect of
initial
participants
Mortality
Raw operative
mortality rate (%)
1.80 3.10 OR ¼ 0.527
(0.327-0.847)
P value ¼ .008Preoperative operative
mortality risk (%)
3.35 3.29
OE mortality ratio 0.54 0.94
Morbidity
Raw major morbidity
rate (%)
12.90 15.20 OR ¼ 0.820
(0.674-0.997)
P value ¼ .047Reoperation for any
reason (%)
5.8 5.4
Stroke (%) 1.4 1.5
Dialysis newly
required (%)
1.9 3.3
Deep sternal wound
infection (%)
1.6 2.2
Prolonged ventilation
(>24 h) (%)
5.6 6.3
Preoperative major
morbidity risk (%)
13.71 13.60
OE morbidity ratio 0.94 1.12
JCVSD, Japan Cardiovascular Surgery Database; OE, observed/expected.
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cations should be targeted to conduct evaluation of medical
standards. For future improvements in the quality ofTABLE 4. Comparison of outcomes: ‘‘initial JCVSD participants
2004’’ versus ‘‘ halfway JCVSD participants 2007’’
Initial
participants:
2004 (n ¼ 44)
Halfway
participants:
2007 (n ¼ 55)
Effect of
initial
participants
Mortality
Raw operative
mortality rate (%)
2.30 3.10 OR ¼ 0.705
(0.457-1.087)
P value ¼ .114Preoperative operative
mortality risk (%)
3.25 3.29
OE mortality ratio 0.71 0.94
Morbidity
Raw major morbidity
rate (%)
13.40 15.20 OR ¼ 0.874
(0.717-1.065)
P value ¼ .180Reoperation for any
reason (%)
5.2 5.4
Stroke (%) 1.5 1.5
Dialysis newly
required (%)
2.8 3.3
Deep sternal wound
infection (%)
1.1 2.2
Prolonged ventilation
(>24 h) (%)
6.5 6.3
Preoperative major
morbidity risk (%)
13.29 13.60
OE morbidity ratio 1.01 1.12
JCVSD, Japan Cardiovascular Surgery Database; OE, observed/expected.
The Journal of Thoracic and Carmedical care in cardiac surgery in Japan, we consider it use-
ful to call attention to postoperative complications as well
as perioperative mortality as performance indicators that
are important from the patient’s perspective.
The activity of the quality improvement initiative in-
cludes multiple components. As operative mortality of half-
way participants of JCVSD is also improved in their initial
phase (see Appendix 1), we think a simple benchmarking
effect (know the performance, measure outcome indicators,
compare own data with national standard) is effective in the
initial participation phase. However, in the second phase
there are several factors to accelerate or inhibit quality im-
provement: how to use a benchmarking report, establish
multidisciplinary collaboration, better regional manage-
ment, share the best practice. Although we simply focused
on the impact of the quality improvement initiative in the
initial phase, further study is better to examine the impact
of the second phase including those site and regional
effects.
In the present study, the indicators we targeted for perfor-
mance evaluation were limited. To make medical standard
evaluation in the cardiac surgery field more meaningful, an-
other important challenge is to improve the framework of
performance evaluation. One such improvement would be
to include the opinions of specialists involved in cardiac
surgery (eg, cardiovascular internists, anesthesiologists,
nurses, and cardiopulmonary bypass technicians) and todiovascular Surgery c Volume 143, Number 6 1367
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through coordination among the various specialists.17 In ad-
dition, it is indispensable to verify whether or not the con-
tents of evaluation are appropriate not only from the
standpoint of those in the clinical setting, who are targeted
for evaluation and are engaged in implementation and im-
provement, but also from the perspectives of hospital ad-
ministrators, insurers, and government administrators. It
will likely be important not only to measure process infor-
mation such as drug administration at discharge,18 which is
related to the patient’s long-term prognosis, but also to carry
out examinations on long-term prognosis and quality of life.
However, if the engagement in improvement imposes an un-
necessarily large burden on other departments and facilities,
continuation of its practice will be difficult. Thus, one pos-
sibility would be to verify the sustainability of incentives
that are appropriate and that the clinical department/facility
can continue. An additional concern is that giving priority to
clinical performance can result in refusing emergency trans-
port or avoiding treatment of serious cases.19,20 In dealing
with such problems, it might be useful to conduct
investigations by targeting not only a single clinical
department at a hospital, but also the quality of clinical
examinations in the field, for the entire region, or by disease.
We thank all members of the Japanese Cardiovascular Surgery
Database for their tireless efforts to improve the quality of cardio-
vascular surgery.References
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APPENDIX 1. Time–trend outcomes of halfway JCVSD participants
after 2007
2007 2008 2009
Mortality
Raw operative mortality rate (%) 3.10 2.1 2.5
Preoperative operative mortality risk (%) 3.3 2.9 3.2
OE mortality ratio 0.94 0.72 0.78
Morbidity
Raw major morbidity rate (%) 15.2 14.4 14.4
Reoperation for any reason (%) 5.4 3.2 3.4
Stroke (%) 1.5 1.5 1.9
Dialysis newly required (%) 3.3 2.2 2.4
Deep sternal wound infection (%) 2.2 1.9 1.6
Prolonged ventilation (>24 h) (%) 6.3 8.3 7.6
Preoperative major morbidity risk (%) 13.6 13.0 13.2
OE morbidity ratio 1.12 1.11 1.09
JCVSD, Japan Cardiovascular Surgery Database; OE, observed/expected.
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